Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial
COVID-19에 대한 Arbidol(Umifenovir)의 효과: 무작위 대조 시험
Randomized Controlled Trial
[키워드] (Lopinavir/ritonavir
adjusted
Admission
age
Analysis
antiviral drugs
ARB
Arbidol
ARMS
assigned
Chest CT
Clinical improvement
contribute
Corona virus
cough
COVID-19
COVID-19 disease
criteria
determine
diagnosis of COVID-19
duration of hospitalization
Dyspnea
Effect
effective
Efficacy
eligible patient
ESR
examined
Fever
Final
final analysis
followed by
group
groups
Health Organization
hospital
Hospitalization
Hydroxychloroquine
ICU admissions
IHD
Improvements
independent
Kaletra
Laboratory
less
Lopinavir
Lopinavir/ritonavir
male
multicenter design
Multiple linear regression
multiple linear regression analysis
Na level
Open-label
open-label randomized controlled trial
oxygen
oxygen saturation
Patient
patients with COVID-19
peripheral
peripheral oxygen saturation
Peripheral oxygen saturation rate
Primary outcome
Randomized controlled trial
Randomly
recruited
relief
Result
Ritonavir
Sample size
significance level
significantly
supportive care
Symptom
the disease
therapy
time
treatments for COVID-19
Trial registration
two group
two groups
variable
WBC
WHO
World Health Organization
[DOI] 10.1186/s12879-020-05698-w PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s12879-020-05698-w PMC 바로가기 [Article Type] Randomized Controlled Trial